{
  "source": "PA-Med-Nec-Aklief.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2307-3\nProgram Prior Authorization/Medical Necessity\nMedication Aklief® (trifarotene) cream\nP&T Approval Date 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nAklief (trifarotene) cream is a retinoid indicated for the topical treatment of acne vulgaris in\npatients 9 years of age and older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Aklief will be approved based on both of the following criteria:\na. Diagnosis of acne vulgaris\n-AND-\nb. History of failure, contraindication, or intolerance to one of the following:\n1) Over-the-counter Differin gel\n2) Tretinoin cream (generic Retin-A)\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Aklief will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n© 2025 UnitedHealthcare Services Inc.\n1\n• Supply limits may be in place.\n4. References:\n1. Aklief [package insert]. Dallas, TX: Galderma; October 2023.\n2. Reynolds, RV, Yeung, H, Cheng, CE, et. al. Guidelines of care for the management of\nacne vulgaris. J Am Acad Dermatol. 2024; 90:1006.e1-e30.\nProgram Prior Authorization/Medical Necessity - Aklief\nChange Control\nDate Change\n6/2023 New program\n6/2024 Annual review. Updated initial authorization to 12 months and updated\nreferences.\n6/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}